BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 1376397)

  • 1. The clinical application of the interferons: a review. NSW Therapeutic Assessment Group.
    Stuart-Harris RC; Lauchlan R; Day R
    Med J Aust; 1992 Jun; 156(12):869-72. PubMed ID: 1376397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Alpha interferons--new therapeutic modalities].
    Bajcetić M; Zigon N; Samardzić R; Beleslin DB
    Med Pregl; 1998; 51(3-4):135-9. PubMed ID: 9611956
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferons. New additions and indications for use.
    Stadler R; Ruszczak Z
    Dermatol Clin; 1993 Jan; 11(1):187-99. PubMed ID: 7679614
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon alfa-2a.
    Williams CD; Linch DC
    Br J Hosp Med; 1997 May 7-20; 57(9):436-9. PubMed ID: 9274677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status of interferon therapy].
    Dittrich C
    Wien Med Wochenschr; 1986 Apr; 136(7-8):163-72. PubMed ID: 2425497
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biologic response modifiers: the interferon alfa experience.
    Koeller JM
    Am J Hosp Pharm; 1989 Nov; 46(11 Suppl 2):S11-5. PubMed ID: 2481396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interferons in the management of viral hepatitis.
    Zein NN
    Cytokines Cell Mol Ther; 1998 Dec; 4(4):229-41. PubMed ID: 10068057
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Criteria for use of interferon alfa-2a or interferon alfa-2b for selected indications in adults.
    Am J Hosp Pharm; 1994 Apr; 51(8):1030-3. PubMed ID: 7518650
    [No Abstract]   [Full Text] [Related]  

  • 9. Current status of interferons in the treatment of cancer.
    Hansen RM; Borden EC
    Oncology (Williston Park); 1992 Nov; 6(11):19-24; discussion 26, 29. PubMed ID: 1280153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The interferons and their use in condyloma acuminata.
    Browder JF; Araujo OE; Myer NA; Flowers FP
    Ann Pharmacother; 1992 Jan; 26(1):42-5. PubMed ID: 1376628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral effects of recombinant interferon alfa and clinical experience in viral infections.
    Schneider HT; Goldmann U
    Arzneimittelforschung; 1989 Dec; 39(12):1608-12. PubMed ID: 2696467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon and other biologic agents for the treatment of Kaposi's sarcoma.
    Krown SE
    Hematol Oncol Clin North Am; 1991 Apr; 5(2):311-22. PubMed ID: 1708760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Possibilities and limits of the use of interferons in the clinic].
    Ludwig CU
    Schweiz Med Wochenschr; 1989 Nov; 119(44):1539-43. PubMed ID: 2479977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C: limits and dose regimen of interferon alfa.
    Prescrire Int; 1998 Oct; 7(37):150-4. PubMed ID: 10915423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interferons.
    Itri LM
    Cancer; 1992 Aug; 70(4 Suppl):940-5. PubMed ID: 1379116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapy of hepatitis C: overview.
    Lindsay KL
    Hepatology; 1997 Sep; 26(3 Suppl 1):71S-77S. PubMed ID: 9305668
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Results of treatment in patients with hairy cell leukemia with splenectomy, alpha-interferon and deoxycoformycin].
    Gotić M; Rolović Z; Radosević N; Draguljac N; Jovanović V; Bogdanović A; Bosković D
    Srp Arh Celok Lek; 2000; 128(7-8):262-70. PubMed ID: 11089434
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chronic hepatitis B: a wider range of therapeutic options.
    Prescrire Int; 2007 Aug; 16(90):157-62. PubMed ID: 17724844
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal.
    Dusheiko GM; Roberts JA
    Hepatology; 1995 Dec; 22(6):1863-73. PubMed ID: 7489999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ischemic colitis with type I interferons used in the treatment of hepatitis C and multiple sclerosis: an evaluation from the food and drug administration adverse event reporting system and review of the literature.
    Salk A; Stobaugh DJ; Deepak P; Ehrenpreis ED
    Ann Pharmacother; 2013 Apr; 47(4):537-42. PubMed ID: 23535814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.